Algorae Pharmaceuticals – Annual General Meeting Results

ASX: 1AI | 5 November 2026

Algorae Pharmaceuticals Limited (ASX: 1AI) ('Algorae' or 'the Company') advises securityholders of the results of the meeting held today.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: investors@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Results of Meeting

Algorae Pharmaceuticals Limited

Annual General Meeting 2026

Thursday, 05 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of the Remuneration Report	P	707,182,205 96.67%	24,036,688 3.29%	15,000	301,492 0.04%	709,188,697 96.72%	24,036,688 3.28%	15,000	-
2 Approval of 10% Placement Capacity	P	728,342,205 96.92%	22,876,688 3.04%	15,000	301,492 0.04%	739,286,197 97.00%	22,876,688 3.00%	15,000	Carried
3 Election of Mr David Gulland as a Director	P	727,342,288 97.00%	22,209,938 2.96%	1,681,667	301,492 0.04%	738,286,280 97.08%	22,209,938 2.92%	1,681,667	Carried
4 Election of Mr Troy Valentine as a Director	P	727,353,533 96.79%	23,776,361 3.16%	48,333	357,158 0.05%	738,353,191 96.88%	23,776,361 3.12%	48,333	Carried
5 Re-election of Mr David Hainsworth as a Director	P	729,975,622 97.13%	21,243,271 2.83%	15,000	301,492 0.04%	740,919,614 97.21%	21,243,271 2.79%	15,000	Carried
6 Ratification of the Appointment of Auditor	P	731,857,022 97.38%	19,361,871 2.58%	15,000	301,492 0.04%	742,801,014 97.46%	19,361,871 2.54%	15,000	Carried
7 Approval of the issue of Performance Rights to Mr David Gulland	P	724,841,161 96.66%	24,726,065 3.30%	1,666,667	301,492 0.04%	735,785,153 96.75%	24,726,065 3.25%	1,666,667	Carried
8 Approval of the issue of Performance Rights to Mr Troy Valentine	P	663,758,072 96.00%	27,325,821 3.95%	0	301,492 0.04%	674,702,064 96.11%	27,325,821 3.89%	0	Carried
9 Approval of the issue of Performance Rights to Mr David Hainsworth	P	706,507,828 96.58%	24,726,065 3.38%	20,000,000	301,492 0.04%	711,514,320 96.64%	24,726,065 3.36%	20,000,000	Carried